Quantcast

Latest Pulmonary hypertension Stories

2014-07-29 08:31:29

-- Total Revenues of $322.8 million SILVER SPRING, Md., July 29, 2014 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) today announced its financial results for the second quarter ended June 30, 2014. "Our continued growth shows that our medicines are reaching increasing numbers of patients suffering from pulmonary arterial hypertension (PAH)," said Martine Rothblatt, Ph.D., United Therapeutics' Chairman and Chief Executive Officer. "The commercial launch this quarter of our...

2014-07-02 23:02:01

A potentially groundbreaking investigational drug designed to treat the painful vaso-occlusive crises that are the hallmark of sickle cell disease has been found to be safe following a clinical trial at UC Davis. Sacramento, CA (PRWEB) July 02, 2014 A potentially groundbreaking investigational drug designed to treat the painful vaso-occlusive crises that are the hallmark of sickle cell disease has been found to be safe following a clinical trial at UC Davis. Vaso-occlusive crises, during...

2014-07-01 16:30:03

HAMPTON, N.J., July 1, 2014 /PRNewswire/ -- Bellerophon Therapeutics, LLC, a clinical stage biotherapeutics company, leveraging its proprietary drug-device technology platform for the development of innovative therapies that address significant unmet medical needs in the treatment of cardiopulmonary and cardiac diseases, today announced that Jonathan Peacock has been appointed Chairman and Chief Executive Officer. Peacock assumes the role of Chairman and Chief Executive Officer from...

2014-06-26 16:25:01

HAMPTON, N.J., June 26, 2014 /PRNewswire/ -- Bellerophon Therapeutics LLC, a clinical stage biotherapeutics company, today announced that it has completed enrollment of its 159-patient Phase 2 clinical trial of INOpulse for the treatment of pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD). PH-COPD is a serious complication of COPD that can significantly affect the health status of patients with this condition. Current standard of care is primarily...

2014-06-25 10:06:13

Brigham and Women's Hospital In a groundbreaking study, researchers from Brigham and Women's Hospital (BWH) have identified a related family of molecules believed to be a major root cause of pulmonary hypertension, a deadly vascular disease with undefined origins. This is one of the first studies to leverage advanced computational network modeling to decipher the molecular secrets of this complex human disease. The study is published online June 24, 2014 in The Journal of Clinical...

2014-06-17 16:25:52

HAMPTON, N.J., June 17, 2014 /PRNewswire/ -- Bellerophon Therapeutics, LLC, a clinical stage biotherapeutics company, today announced that it has completed enrollment of its 80-patient Phase 2 clinical trial of INOpulse for the treatment of pulmonary arterial hypertension (PAH). PAH is a life-threatening, progressive disorder characterized by abnormal constriction of the arteries of the lung, leading to increased blood pressure in the lungs and abnormal strain on the heart's right...

2014-05-20 10:04:10

American Thoracic Society Pulmonary hypertension patients from lower socioeconomic groups present for initial evaluation at a more advanced disease state than those from higher income groups, according to a new study presented at the 2014 American Thoracic Society International Conference. "Lower socioeconomic status is associated with reduced access to health care and negative effects on health status, but data on its effects on the care of patients with pulmonary hypertension is...

2014-05-20 10:02:40

American Thoracic Society In patients with congestive heart failure, obesity and a larger waist size have paradoxically been associated with a better prognosis in the prior investigations. This effect, known as the obesity paradox phenomenon, is now being demonstrated in patients with severe pulmonary hypertension. "Obesity-related illnesses, particularly obesity hypoventilation syndrome and sleep apnea, may play a role in the development of pulmonary hypertension, and so we examined...

2014-05-19 14:50:02

American Thoracic Society Patients with chronic pulmonary thromboembolic disease may benefit from pulmonary thromboendarterectomy (PTE), even if the patients don't have severe pulmonary hypertension, according to University of California, San Diego, researchers. The study was presented at the 2014 American Thoracic Society International Conference. UCSD pioneered PTE in the 1970s for patients who suffered from chronic thromboembolic pulmonary hypertension (CTEPH). During PTE,...

2014-05-12 23:08:41

Pulmonary arterial hypertension – a deadly, incurable lung condition – is one of only sixteen disease states FDA will focus on during the first three years of the Patient Focused Drug Development Initiative. The meeting represents a historic opportunity for patient input. Silver Spring, MD (PRWEB) May 12, 2014 On Tuesday, May 13, the Food and Drug Administration and the Pulmonary Hypertension Association will host a unique conversation between FDA drug reviewers and pulmonary arterial...


Word of the Day
mallemaroking
  • Nautical, the visiting and carousing of sailors in the Greenland ships.
This word is apparently from a confusion of two similar Dutch words: 'mallemerok,' a foolish woman, and 'mallemok,' a name for some persons among the crew of a whaling vessel.